ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by ValuEngine

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Wednesday, ValuEngine reports.

Several other brokerages have also recently commented on PRQR. Zacks Investment Research upgraded shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 10th. BidaskClub lowered shares of ProQR Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $28.67.

NASDAQ PRQR traded down $0.52 on Wednesday, hitting $8.87. 3,175 shares of the company’s stock traded hands, compared to its average volume of 207,596. The company has a quick ratio of 10.08, a current ratio of 10.08 and a debt-to-equity ratio of 0.14. ProQR Therapeutics has a 1-year low of $6.75 and a 1-year high of $24.00. The stock’s 50-day moving average price is $9.31. The firm has a market cap of $346.36 million, a price-to-earnings ratio of -6.86 and a beta of 0.11.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.05). As a group, equities research analysts forecast that ProQR Therapeutics will post -1.65 EPS for the current year.

Several large investors have recently bought and sold shares of the company. California Public Employees Retirement System purchased a new position in shares of ProQR Therapeutics during the 4th quarter valued at $660,000. BlackRock Inc. purchased a new position in shares of ProQR Therapeutics during the 4th quarter valued at $11,064,000. Northern Trust Corp purchased a new position in shares of ProQR Therapeutics during the 4th quarter valued at $666,000. Geode Capital Management LLC lifted its stake in shares of ProQR Therapeutics by 14.1% during the 4th quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 2,375 shares in the last quarter. Finally, Barclays PLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter valued at $51,000. 61.70% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

See Also: How Do Front-End Loads Impact an Investment?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.